Future investigations that explore gC1qR-directed therapies in the context of AIS will draw upon these established modalities and binding sites that have proven to be relevant to gC1qR and its role in generalized inflammation, vascular permeability, cancer, and infection. This evidence concerns the gene C1QBP and androgen insensitivity syndrome.